Dr. Frank Breveis a clinical pharmacist with extensive experience across various healthcare settings, including hospitals, long-term care facilities, dialysis centers, surgical centers, assisted living, medical day care, PACE programs, narcotic treatment programs, and behavioral health facilities. They also consult for the pharmaceutical and biotechnology industries, as well as state and federal government agencies. Key areas of expertise include Medication Therapy Management, optimizing drug use to promote rational therapy and reduce adverse event risks, inspections and regulatory compliance, and the development and review of policies and procedures. They are also involved in Quality Assurance, Continuous Quality Improvement, pharmaceutical outcome studies, and legal consulting in medical malpractice and product liability cases. Dr. Frank Breve specializes in geriatrics (board certified), psychiatry/neurology (expert in psychopharmacology), oncology (with teaching hospital experience), nephrology (Pharma renal division experience), and drug diversion risk reduction, having served as a consultant for the United States Department of Justice and the Drug Enforcement Agency. Their work spans a broad spectrum of regulatory compliance, quality improvement, and patient safety, making them a sought-after consultant in the healthcare industry.

Dr. Ridhurkar is the CEO of RidNova Pharmaceuticals and a Subject Matter Expert based in Barcelona with over 20 years of experience in pharmaceutical complex formulation development and scientific leadership. His expertise spans advanced drug delivery technologies, including nanotechnology, liposomes, hot-melt extrusion, continuous manufacturing, spray drying, lyophilization, solid dispersions, 3D printing, microencapsulation, and long-acting injectable formulations. He has extensive experience in small molecules, biosimilars, peptides, proteins, and specialty formulations, including 505(b)(2) and hybrid products. Dr. Ridhurkar is actively advancing the application of Artificial Intelligence (AI) in pharmaceutical drug delivery, formulation optimization, predictive modeling, and next-generation development strategies. He recently contributed to and published a book chapter on AI-embedded systems for brain targeting with Elsevier, highlighting his focus on integrating AI-driven approaches to accelerate development timelines, enhance formulation efficiency, and improve therapeutic outcomes. He holds an M.Pharm and PhD in Pharmaceutics from Indian Institute of Technology (BHU) Varanasi, has authored over ten peer-reviewed publications, and holds nine patents in advanced drug delivery and pharmaceutical technologies.

Dr. Karen Caon holds a PhD and an MSc in Environmental Sciences and has a background in Biology. She has extensive international professional experience and currently works as a Reference Materials Specialist in the pharmaceutical sector, providing support to pharmaceutical, academic, diagnostic, and industrial segments across different countries. She has worked with research teams and has contributed to, as well as expanded, her knowledge in departments such as Compliance within the Life Sciences industry. Dr. Caon also has academic experience as a lecturer in Biology and Ecology, with subject-matter expertise in genotoxicity, cytotoxicity, ecotoxicology, and biomonitoring.

Professor Eugene Jamot Ndebia is an esteemed academic specializing in Medical Physiology, Epidemiology and Biostatistics. With an NRF C3 rating, he is recognized for his impactful contributions to research and teaching. He currently serves as the Chairperson of the Human Research Ethics Committee (WSU-HREC) and leads the Cancer Epidemiology Research Group (CERG) within the Faculty of Medicine and Health Sciences at Walter Sisulu University, South Africa. Prof. Ndebia’s research primarily focuses on prevention strategies and the early detection of cancers, emphasizing interventions that save lives in vulnerable populations. His expertise extends to a wide range of public health challenges, particularly in low-resource settings. His work has garnered significant recognition, with an impressive publication record that includes numerous peer-reviewed articles cited extensively in academic literature. As a dedicated mentor, Prof. Ndebia has guided many postgraduate students, fostering the next generation of researchers and health professionals. His ability to translate complex epidemiological concepts into actionable insights has inspired his mentees to pursue impactful careers. With his extensive experience, scholarly achievements, and dedication to mentorship and community service, Prof. Eugene Jamot Ndebia remains a leading figure in the fields of Epidemiology and Biostatistics, contributing significantly to global efforts to improve health outcomes.

Dr. Céline Tiffon is a medical writing consultant in Medical Affairs for the biopharmaceutical industry and an independent researcher based in Yvelines, France. With a strong background in biochemistry, cell biology, and physiology, she earned her Ph.D. in tumor biology in 2008. After her doctoral studies, she completed postdoctoral research in onco-hematology and endocrine toxicology at institutions across the UK and France. Holding certifications in clinical research and regulatory medical writing, Dr. Tiffon previously served as a clinical project manager in the pharma industry. She later joined the French National Cancer Institute as a scientific officer. In this role, she managed projects, analyzed clinical program data, and evaluated biology research initiatives. Her research focuses on oncology, epigenetics, inflammation, cell differentiation, and environmental factors. Dr. Tiffon has authored 25 papers, including five key articles. She published a book in 2019 based on her Ph.D. thesis, alongside five book chapters written between 2020 and 2022. Beyond her own writing, she regularly reviews manuscripts for scientific journals and presents her research at international conferences.

Dr. Rao, Ph D (ANU), Ph D (World University, London), D. Sc (Microbiology), M.D.(Medicine )(Hon) (USA) ,FRCP(Edinburgh),is an eminent academician and researcher, a keen votary of medical education and research, and an able administrator and possessing nearly five decades of rich and satisfying teaching, research experience in Medicine and Infectious Diseases. Dr. Rao assumed multiple academic and administrative positions, like professor of Medical Microbiology, Parasitology, Immunology, and Virology in many universities, and many medical colleges in India, China, Nepal, Libya, America, and the Philippines. Prof. Rao, currently working as Professor of Microbiology, Chaiman National Council of India, and World Academy of Medical Sciences, Netherlands in Europe. Recently, Dr Rao received a Fellowship from the Royal College of Physicians (Edinburgh). It was established by royal charter in 1681.RCP fellows’ standout contributions to medicine are recognised, and their voice is amplified to shape the future of healthcare. Fellow of the Royal College of Physicians, Edinburgh, is a prestigious postgraduate qualification awarded to doctors in recognition of their expertise and contribution to their speciality. He is one of the very few Medical Microbiologists of India, conferred with an MD (Medicine) (USA) degree for his contribution in the field of Medical Microbiology, and Immunology, by Avalon University School of Medicine, Ohio, USA. Dr. Rao received the Official World Record Award 2023. The official world record, Barcelona, Spain, Europe, has approved his record achievement. India Book of Records-2021 ((National recognition and International endeavours).The extraordinary achievements are published in the Washington Post, BBC, New York Times, The Telegraph, etc. Dr Rao, received fellowship from Indian Virology Society in 2022.

Yanying Liu is a professor currently teaching Medical Pathogenic Microbiology and Parasitology, Immunology, and Biochemistry at the Qingdao Huanghai University in China. She received her Ph.D. in Neurobiology from the Capital Medical University(China). Dr. Liu has presided over and completed special funding projects from the China Postdoctoral Science Foundation and first-class funding projects from the China Postdoctoral Science Foundation; Participated in several National Natural Science Foundation projects of China and NIH RO1 projects (USA). Dr. Liu currently serves as a reviewer and/or as an Editor Board Member for over 30 SCI/SCIE journals. Her current research areas are related to hypoxia, Alzheimer's disease, aging, and stroke

Dr. Barry Hardy is the Chief Executive Officer (CEO) at Edelweiss Connect where he is leading its team supporting the development of new integrating solutions in industrial product design and safety assessment and the translation of research methods to industrial practice. Example recent commercial developments include the creation of the SaferWorldbyDesign platform (https://www.saferworldbydesign.com/), and the development of the SaferSkin (https://saferworldbydesign.com/saferskin/) and EdelweissData products (https://saferworldbydesign.com/edelweissdata/). He is currently leading the development of risk assessment knowledge infrastructure and solutions, including new approach methods, SaferbyDesign, sustainability and next generation risk assessment solutions (https://www.risk-hunt3r.eu). He coordinated the OpenTox project in predictive toxicology and is currently President of the OpenTox Association, founded in 2015 as an international non-profit organisation promoting an open knowledge community approach to new methods in predictive toxicology and the 3Rs principles of the refinement, reduction and replacement of animal experiments. Previously, he led the infrastructure development for the IMI EBiSC stem cell banking project, the eNanoMapper project developing solutions supporting nanotechnology safety assessment, OpenRiskNet infrastructure development supporting risk assessment, and knowledge infrastructure development for ACEnano, NanoCommons and EU-ToxRisk. Dr. Hardy obtained his Ph.D. in 1990 from Syracuse University working in computational science. He was a National Research Fellow at the FDA Center for Biologics and Evaluation, a Hitchings-Elion Fellow at Oxford University and CEO of Virtual Environments International. He was a pioneer in the 1990s in the development of Web technology applied to virtual scientific communities and conferences. He has developed technology solutions for internet-based communications, tutor-supported e-learning, laboratory automation systems, and computational science and informatics. In recent years he has also been active in the field of knowledge management as applied to supporting innovation, communities of practice, and collaboration, with a particular focus on developing new evidence-based methods in predictive toxicology and safety assessment, including development of Integrated Approaches to Testing and Assessment (IATAs) and their application to industrial and regulatory practice.

Ahmet has completed his bachelor in Chemical and Mechanical Engineering and has been working for about 23 years in the field of textile management with various reputed retail brands and training across Europe and US. Ahmet has conducted over 2800 audits on behalf of international brand clients over the last 12 years. Being a HIGG FEM trainer and Chemical specialist verifier, Ahmet has conducted more than 250 Higg verifications in 3 years. Ahmet has been working for a long time as a sustainability profession in the textile and apparel industry. He has conducted training for sustainability practitioners in the industry in the Istanbul Technical University as an expert. Ahmet is certified by the Republic of TÃrkiye Ministry of Energy and Natural Resources for Energy management. Dyeing machines isolation feasibility on energy Management for Europe Brands in Textile , Energy Management and Energy ministry consumption declarations for different organizations, ISO 50001 feasibility, Coal, Natural Gas, LNG versus BIOMASS feasibility check are some of his noteworthy works in the field of Energy management in last 15 years.

An intensive care physician and clinical toxicologist, Dr. Regis Bédry has devoted most of his career to the management of acute poisonings, envenomations and toxicological emergencies, in close connection with intensive care medicine, emergency medicine, pharmacovigilance and public health. Trained in Bordeaux and Marseille, France, and having worked at the Poison Control Centers of Marseille and Bordeaux, he held major hospital responsibilities, notably as Head of the Department of Intensive Care and Medical Toxicology at the Clinique Mutualiste in Pessac, France, and later as Medical Director and hospital practitioner of the Interregional Secure Hospital Unit at Bordeaux University Hospital until his retirement in January 2024. His career is marked by in-depth and widely recognized expertise in clinical toxicology and toxinology. His work has covered many areas, including severe drug poisonings, antidotes, gastrointestinal decontamination and extracorporeal elimination of toxicants, carbon monoxide poisoning, glyphosate, cardiotoxic substances, caustic agents, pesticides, heavy metals, illicit drugs, and both terrestrial and marine envenomation. He made a particularly significant contribution to the understanding of mushroom poisonings, including the identification of emerging rhabdomyolysis syndromes associated with mushrooms previously considered edible, as well as to the study of toxicological risks related to venomous or poisonous marine species, especially in the Mediterranean area. As an author, co-author or editor of numerous national and international publications, book chapters and practical guides in toxicology, he has also maintained a strong teaching activity in medical toxicology for medical students, residents, healthcare professionals, French and international universities, and specialized university diploma programmed. His scientific involvement includes the organization of toxicology and emergency medicine meetings, participation in thesis committees and international recommendations, and active membership in learned societies such as the Société de Toxicology Clinique and the European Association of Poisons Centers and Clinical Toxicologists, where he served as board member, scientific committee member and later emeritus member. Overall, his career reflects a cross-disciplinary and long-standing expertise in the assessment, management, teaching and dissemination of knowledge in clinical toxicology.

Fatima Ezzahra Khaddach is a Moroccan pharmacologist, toxicologist, and researcher specializing in venom toxicology, pharmacokinetics, pharmacodynamics, and healthcare quality systems. Holding a PhD in Pharmacology and Toxicology, she has developed an interdisciplinary career combining scientific research, higher education, and Quality, Health, Safety, and Environment (QHSE) expertise across healthcare, pharmaceutical, and industrial sectors. Dr. Khaddach is particularly recognized for her research on the pharmacokinetic and pharmacodynamic effects of venom from dangerous Moroccan snake species using experimental rabbit models. Her work focuses on understanding the toxicological mechanisms, systemic effects, venom distribution, and physiological impact of envenomation, with the objective of improving clinical management, antivenom strategies, and therapeutic interventions for snakebite victims. Through experimental studies and toxicological analysis, her research contributes to advancing scientific knowledge on venom-induced pathophysiological alterations and public health challenges related to snake envenomation in Morocco. Her scientific interests extend to pharmacology, toxicology, patient safety, public health, and biomedical research. She is dedicated to bridging laboratory research with practical healthcare applications, particularly in the fields of toxic exposure management and emergency care related to venomous bites and poisoning. Alongside her academic and research activities, Dr. Khaddach has extensive professional experience in QHSE management and consulting. She has participated in the implementation, auditing, and continuous improvement of integrated management systems in accordance with international standards including ISO 9001, ISO 14001, and ISO 45001. Her competencies include quality assurance, regulatory compliance, occupational health and safety, environmental management, internal auditing, risk assessment, and continuous improvement processes. Known for her scientific rigor, analytical thinking, and multidisciplinary expertise, Dr. Khaddach combines advanced research skills with practical operational experience. She is passionate about innovation, scientific excellence, and the promotion of safer healthcare and industrial environments. Dr. Khaddach also has a strong interest in academic teaching and mentorship, aspiring to contribute to university education and scientific research initiatives in pharmacology, toxicology, and health sciences. She is fluent in French, professionally proficient in English, and has working knowledge of Spanish, enabling her to collaborate within international scientific and professional networks.

Dr. Lachhman Das Singla is an internationally recognized veterinary parasitologist with more than 32 years of experience in research, teaching, extension, and scientific publishing. He obtained his B.V.Sc. & A.H. (1989), M.V.Sc. (1991), and Ph.D. (2001) from Punjab Agricultural University, Ludhiana, India. He has published more than 200 peer-reviewed research and review articles in reputed international and national journals with over 5304 citations, h-index 42, and i10-index 130. His research expertise includes veterinary parasitology, vector-borne diseases, tick-borne infections, antiparasitic drug resistance, and animal health management. Dr. Singla has extensive editorial experience and is currently serving as Associate Chief Editor of the Indian Journal of Animal Research. He has served as Editor-in-Chief, Associate Editor, Academic Editor, Regional Editor, or Editorial Board Member for more than 40 national and international journals, including Veterinary Medicine and Science, Biomed Research International, and International Journal of Zoological Research. He has also reviewed manuscripts for more than 100 national and international scientific journals, including Journal of Equine Veterinary Science, Veterinary Parasitology, Preventive Veterinary Medicine, Acta Tropica, Frontiers in Veterinary Science, and Ticks and Tick-borne Diseases. He is a Fellow of the Royal Society of Tropical Medicine and Hygiene (London), Fellow of the National Academy of Veterinary Sciences (India), and Fellow of the Indian Association for the Advancement of Veterinary Parasitology. Dr. Singla has actively participated in scientific meetings and collaborations across several countries including Australia, Canada, China, Denmark, England, France, Italy, Malaysia, New Zealand, Thailand, USA, and Vietnam. His long-standing commitment to scientific publishing, peer review, research ethics, and academic excellence makes him well suited for editorial responsibilities in international veterinary journals.

Dr. Pavani Gonnabathula is a clinical pharmacology and toxicology expert with more than a decade of experience in pharmacokinetics, toxicology, PBPK/PBTK modeling, PK/PD, and model-informed product evaluation. She has held research roles with the U.S. FDA and CDC and has contributed to scientific work spanning drug development, environmental toxicology, human health risk assessment, and regulatory science. Her expertise includes physiologically based pharmacokinetic modeling, toxicokinetic assessment, pediatric and maternal health-related exposure evaluation, developmental toxicology, and safety-focused scientific decision-making. Dr. Gonnabathula’s work emphasizes translating complex pharmacological and toxicological data into clear, evidence-based guidance to support safer therapeutic, environmental, and public health decisions. She is particularly interested in applying computational modeling, IVIVE, and regulatory science approaches to improve risk assessment and protect vulnerable populations, including children and pregnant individuals.

Dr. Eva Villalba-Riquelme is a postdoctoral researcher at the Wolfson Institute for Biomedical Research at University College London. She is a member of the Molecular Nociception group led by Prof. John Wood, where she investigates the neurobiology of pain. Dr. Villalba-Riquelme obtained her PhD in Molecular and Cellular Biology from Miguel Hernández University under the supervision of Prof. Antonio Ferrer, investigating the mechanisms underlying chemotherapy-induced peripheral neuropathies. During her doctoral research, she established two in vitro preclinical models to facilitate the research of paclitaxel- and oxaliplatin-induced neuropathies and uncovered novel details on the direct and time-dependent effect of these agents on sensory neurons. Her work identified key alterations occurring in NaV and TRP ion channels, and revealed a sexual dimorphism in neuronal responses, highlighting promising analgesic targets for cancer pain relief.

Malak Bourai holds a background in neuroscience with a specialization in neurobiology and a particular interest in neurodegenerative diseases and memory research. She completed her Master’s degree with a thesis focused on neuro-bioimaging parameters involved in cognitive decline related to Alzheimer’s disease, a project that strengthened her passion for exploring the mechanisms underlying memory impairment. Her professional journey reflects à balance between scientific expertise and applied research. She has worked in the fields of diagnostic imaging. Currently, she serves as a Senior Analyst in pharmacotoxicology at the Research and Development Center of Saidal Group, where she contributes to projects involving in vitro models, toxicological analysis, and preclinical research. Her work in the laboratory also includes responsibilities related to animal facilities and advanced testing, providing her with hands-on experience in translational research. Driven by a long-term vision of contributing to neuroscience, Malak is particularly interested in bridging pharmacology, toxicology, and neurobiology to better understand and address neurodegenerative disorders. She aspires to pursue a PhD in neuroscience, focusing on the development of innovative strategies for studying memory decline and cognitive disorders. Her multidisciplinary profile, combining laboratory research with communication skills, positions her as a promising researcher ready and excited to contribute to scientific innovation.

Zineb Ouhemmou is a PhD student in Physiopathology, Pharmacology, and Toxicology at Hassan II University of Casablanca, Morocco, in collaboration with the Institut Pasteur du Maroc. She holds an International Master's degree in Health Sciences from Hassan II University and Aix-Marseille University. She is affiliated with the Laboratory of Toxins and Venoms at the Institut Pasteur du Maroc, where her doctoral research focuses on the local pathophysiological disorders induced by snakebite envenomation. Her research interests include toxicology, physiopathology,and the development of artificial intelligence–based diagnostic approaches for assessing venom-induced tissue damage. Her current work aims to improve the understanding of snake venom-induced tissue damage and contribute to the development of innovative diagnostic and therapeutic strategies for snakebite envenomation.